9 , e1003713 (2013)
The combination of Mounjaro-induced nausea and alcohol consumption creates a significantly higher risk of vomiting, prolonged nausea, and general gastrointestinal distress particularly in the first 812 weeks of treatment
QU ES
Phase III results for retatrutide are set to be released later in 2025 and in early 2026, but an earlier phase II trial recorded between a 7.2% and 17.5% reduction in body weight after 24 weeks, depending on the dose (7.2% on 1mg, 17.5% on 12mg), and up to a 24.2% reduction in body weight after 48 weeks for those on 12mg (-8.7% change for those on 1mg) 8
The results of this review described the effects of administering Met and GSH alone and in coformulation with other compounds on body weight, reproductive organ weight, sperm count, sperm motility, morphology, histopathology, hormone assessment, testicular antioxidants, and OS status in diabetic male rodent models
C.KeenC.LawrenceP.KinnerS